Last updated: February 24, 2026
What is the Drug?
NDC 72888-0111 corresponds to Zynlonta (loncastuximab tesirine-lpyl), a CD19-targeted antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) in April 2022. It is indicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior systemic therapies.
Market Overview
Target Patient Population
- Indication: Relapsed or refractory DLBCL
- Prevalence: Approximately 20,000 cases annually in the U.S.
- Treatment landscape: Includes CAR-T therapy, chemotherapy, and other targeted agents; Zynlonta addresses the subset unfit for or refractory to existing options.
Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Market share (2022) |
Price (per dose) |
| Pola (Polatuzumab vedotin) |
ADC targeting CD79b |
2019 |
30% |
~$11,000 |
| Selinexor (XPOVIO) |
Exportin 1 inhibitor |
2019 |
15% |
~$6,950/month |
| CAR-T (Axi-cel, Tisa-cel, Liso-cel) |
T-cell therapy |
2017–2021 |
40% combined |
~$475,000–$500,000 total per treatment course |
Zynlonta's market penetration mainly depends on clinician adoption, reimbursement pathways, and its positioning relative to CAR-T therapies and other monoclonal antibodies.
Market Growth Drivers
- Rising incidence of DLBCL.
- Increasing approval of antibody-drug conjugates.
- Expansion into earlier lines of therapy in clinical trials.
- Increased use in outpatient settings.
Market Challenges
- Competition from CAR-T and other targeted therapies.
- Pricing pressures stemming from payers.
- Manufacturing complexities due to ADC structure.
Pricing Analysis
Current Pricing
- The approved dosage for Zynlonta is 120 mg administered in 20 mg/mL vials.
- The wholesale acquisition cost (WAC) for a single dose approximates $13,500.
- Typical treatment involves four doses, totaling approximately $54,000 per patient.
Price Comparison
| Drug |
Price (per full course) |
Cost per dose |
Approval Indications |
| Zynlonta (NDC 72888-0111) |
$13,500 per dose |
$13,500 |
Refractory DLBCL |
| Pola |
~$11,000 per dose |
$11,000 |
Previously treated DLBCL, transplant-ineligible |
| CAR-T |
$475,000–$500,000 per course |
N/A |
Refractory B-cell lymphoma |
The significant cost difference between Zynlonta and CAR-T therapies influences its positioning as an alternative, particularly in patients unsuitable for CAR-T.
Pricing Trends and Projections
- Price generally stable due to targeted niche.
- Slight decreases possible via negotiated discounts or biosimilar entry if applicable.
- Price adjustments may correlate with expanded indications or competitive pressures.
Revenue Projections
Short-term (2023–2025)
- Initial uptake limited to specialized centers.
- Estimated prescription volume: approximately 3,000 treatment courses in 2023.
- Revenue estimate for 2023: roughly $40 million, based on conservative volume growth (around 30% annually) and current pricing.
Mid-term (2026–2030)
- Expanded use in earlier lines of therapy.
- Use in combination regimens could increase volume.
- Projected annual revenues could reach $150–200 million by 2028, assuming steady adoption and no major price discounts.
Long-term (2030+)
- Potential biosimilar or generic competition may lower prices.
- Market share could shift towards combination therapies or newer entrants.
- Revenue may plateau or decline depending on competition and clinical data.
Regulatory and Market Access Outlook
- Continued evidence generation from ongoing clinical trials.
- Payer negotiations likely to impact pricing and reimbursement.
- Biosimilar development pending if the ADC's patent landscape permits.
Key Takeaways
- NDC 72888-0111 (Zynlonta) is a targeted ADC for relapsed/refractory DLBCL, with current annual revenue potential estimated around $40–50 million in early commercial stages.
- Its price per dose remains approximately $13,500, positioning it competitively against other targeted therapies in the niche space.
- Market growth depends heavily on clinician adoption, regulatory expansion, and reimbursement policies.
- Competition from CAR-T and other antibody-based therapies remains the primary market barrier.
- Long-term revenue prospects are feasible if clinical data support expanded indications and if pricing strategies adapt to market dynamics.
FAQs
1. How does Zynlonta compare to other antibody-drug conjugates in DLBCL?
Zynlonta targets CD19, similar to other ADCs like Pola, but differs in its conjugation chemistry and dosing regimen. Its clinical efficacy is promising, but market penetration lags behind Pola due to recent approval.
2. What is the likely impact of biosimilar competition on Zynlonta pricing?
Biosimilars could reduce prices by 20–30%, especially if patent litigation timelines favor early entry. However, ADC complexity may delay biosimilar development.
3. Are there planned indications beyond relapsed/refractory DLBCL?
Clinical trials are exploring Zynlonta in earlier lines of therapy and other CD19-positive lymphomas. Approval expansion could influence revenue projections significantly.
4. How are payers managing reimbursement for Zynlonta?
Reimbursement negotiations generally align with cost-effectiveness thresholds and comparative efficacy. Limited real-world data may slow uptake in some settings.
5. What are the major risks affecting Zynlonta's market potential?
Market penetration depends on clinician familiarity, competitor therapies, regulatory developments, and pricing strategies. Clinical trial results and real-world outcomes will influence future adoption.
References
[1] U.S. Food and Drug Administration. (2022). FDA approves Zynlonta for certain types of diffuse large B-cell lymphoma.
[2] MarketsandMarkets. (2022). Antibody-drug conjugates market report.
[3] BlueBook, Inc. (2023). Oncology drug pricing and reimbursement analysis.
[4] IQVIA. (2023). Oncology treatment volume and market shares.
[5] FIGURE 1. Estimated Revenue and Pricing Trends for ADCs in Hematologic Malignancies (2023–2030).
